Dr Vetticaden will be a member of Cubist’s executive team and report to Mike Bonney, Cubist’s president and CEO. Dr Vetticaden will lead the development and implementation of clinical strategy for Cubist’s clinical programs, while managing and developing clinical research, medical affairs, clinical operations, statistics and data management, and pharmacovigilance.
Dr Vetticaden has more than 22 years of experience as a researcher and medical professional. Dr Vetticaden has been consulting since leaving his position as senior vice president and chief medical officer at Maxygen, which he held from February 2007 to August 2008.
Mr Bonney said: “We are fortunate to have found in Dr Vetticaden a gifted drug developer, clinician, and leader, who will be able to provide substantive contributions immediately. All of his skills will be called upon early and often as Cubist continues to grow.”